← Back to Search

Antioxidant

Antioxidant Therapy for Obstructive Sleep Apnea

Phase 2 & 3
Waitlist Available
Led By Rachel Jen, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
More than 9 minutes/night spent below oxygen saturation of 90%.
Medically stable adult patients between 35 and 60 years of age with moderate to severe OSA (AHI>15 events/hour by a full night in-laboratory polysomnogram or ambulatory study)
Must not have
Subjects who have diabetes.
Subjects who are taking antioxidants.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks

Summary

This trial tests whether an antioxidant called alpha lipoic acid (ALA) can improve heart health in adults with moderate to severe sleep apnea. Sleep apnea causes breathing problems during sleep and increases the risk of heart disease. ALA may help by reducing harmful substances that damage blood vessels and cause inflammation. Alpha lipoic acid (ALA) is a potent antioxidant with anti-inflammatory properties.

Who is the study for?
Adults aged 35-60 with moderate to severe obstructive sleep apnea, who haven't adhered to CPAP therapy and spend over 9 minutes a night with low oxygen levels. Excluded are those with autoimmune diseases, excessive daytime sleepiness, cardiovascular disease, recent OSA treatment, diabetes, chronic inflammatory diseases or on anti-inflammatory/immunosuppressive drugs.
What is being tested?
The study tests if antioxidants (Alpha Lipoic Acid) improve heart health in sleep apnea patients by comparing it against a placebo. Participants will be randomly assigned to either the antioxidant or placebo group without knowing which one they're taking and monitored for blood vessel function and cardiac risk markers.
What are the potential side effects?
While not specified in the provided information, common side effects of Alpha Lipoic Acid may include skin rash, muscle cramp, headache or tingling sensation; however these vary from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My oxygen levels drop below 90% for over 9 minutes at night.
Select...
I am 35-60 years old with moderate to severe sleep apnea (AHI>15).
Select...
I have not used CPAP therapy consistently for the past month or have declined it.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have diabetes.
Select...
I am currently taking antioxidants.
Select...
I have a long-term inflammatory condition like rheumatoid arthritis or asthma.
Select...
My oxygen levels drop significantly when I sleep.
Select...
I have been diagnosed with cardiovascular disease.
Select...
I often feel very sleepy during the day.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Level of C reactive protein (CRP)
Reactive hyperemia index (RHI)
Secondary study objectives
Augmentation Index (AI)
Plasma level of 8-hydroxy-2-deoxy guanosine (8-OHdG)
Plasma level of 8-isoprostane
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Alpha Lipoic AcidExperimental Treatment1 Intervention
alpha lipoic acid PO 600 mg daily for 8 weeks
Group II: PlaceboPlacebo Group1 Intervention
placebo PO daily for 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Alpha Lipoic Acid 600 MG Oral Tablet
2023
N/A
~60

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Obstructive Sleep Apnea (OSA) is commonly treated with Continuous Positive Airway Pressure (CPAP) therapy, which keeps the airway open during sleep, and lifestyle changes such as weight loss. Another emerging treatment involves the use of antioxidants to reduce oxidative stress. OSA causes repetitive airway collapse, leading to intermittent hypoxia and reoxygenation, which generates reactive oxygen species (ROS) and contributes to oxidative stress. This oxidative stress is linked to cardiovascular complications in OSA patients. Antioxidants help neutralize ROS, potentially improving cardiovascular health and reducing inflammation and oxidative damage. This approach is being studied to determine its efficacy in improving blood vessel function and reducing cardiac risk markers in OSA patients.
Chronic intermittent hypoxia impaired collagen synthesis in mouse genioglossus via ROS accumulation: A transcriptomic analysis.Protective effects of mitochondria-targeted antioxidants and statins on cholesterol-induced osteoarthritis.Oxidative stress in obstructive sleep apnea and intermittent hypoxia--revisited--the bad ugly and good: implications to the heart and brain.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,465 Previous Clinical Trials
2,485,417 Total Patients Enrolled
Rachel Jen, MDPrincipal InvestigatorUniversity of British Columbia

Media Library

Alpha Lipoic Acid (Antioxidant) Clinical Trial Eligibility Overview. Trial Name: NCT05009901 — Phase 2 & 3
Sleep Apnea Research Study Groups: Alpha Lipoic Acid, Placebo
Sleep Apnea Clinical Trial 2023: Alpha Lipoic Acid Highlights & Side Effects. Trial Name: NCT05009901 — Phase 2 & 3
Alpha Lipoic Acid (Antioxidant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05009901 — Phase 2 & 3
Sleep Apnea Patient Testimony for trial: Trial Name: NCT05009901 — Phase 2 & 3
~23 spots leftby Nov 2025